和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02256 和誉-B

已收盘 11-22 16:08:13

4.180

-0.450

-9.72%

最高4.650	最低4.180	成交量330.20万
今开4.600	昨收4.630	日振幅10.15%
总市值28.69亿	流通市值28.69亿	总股本6.86亿
成交额1,433万	换手率0.48%	流通股本6.86亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02256","market":"HK","secType":"STK","nameCN":"和誉-B","latestPrice":4.18,"timestamp":1732262893015,"preClose":4.63,"halted":0,"volume":3302000,"delay":0,"floatShares":686366350,"shares":686366350,"eps":-0.714948,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.45,"latestTime":"11-22 16:08:13","open":4.6,"high":4.65,"low":4.18,"amount":14334338,"amplitude":0.101512,"askPrice":4.2,"askSize":5000,"bidPrice":4.18,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.02700706610515172,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"listingDate":1634054400000,"adjPreClose":4.63,"openAndCloseTimeList":[[1732239000000,1732248000000],[1732251600000,1732262400000]],"volumeRatio":1.153372,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02256/tweets","defaultTab":"tweets","newsList":[{"id":"2485288285","title":"和誉完成II期临床研究首例胃癌患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2485288285","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485288285?lang=zh_cn&edition=full","pubTime":"2024-11-22 13:46","pubTimestamp":1732254380,"startTime":"0","endTime":"0","summary":"财中社11月22日电和誉-B（02256）发布自愿性公告，宣布其附属公司上海和誉生物医药科技有限公司已完成一项II期临床研究的首例胃癌患者给药。该研究旨在评估口服PD-L1小分子抑制剂ABSK043与FGFR2/3小分子抑制剂ABSK061联合或不联合化疗在FGFR2/3改变的转移性或不可切除的实质瘤患者中的安全性及有效性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411223247943127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2485340411","title":"和誉-B(02256)：口服PD-L1小分子抑制剂ABSK043联合FGFR2/3小分子抑制剂ABSK061治疗实体瘤的II期临床完成首例胃癌患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2485340411","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485340411?lang=zh_cn&edition=full","pubTime":"2024-11-22 12:25","pubTimestamp":1732249557,"startTime":"0","endTime":"0","summary":"剂量递增将评估ABSK061及ABSK043在FGFR2/3激活改变或过表达的转移性/不可切除的晚期实体瘤患者中的安全性、耐受性、初步疗效和PK特征，并推荐用于扩展期的给药剂量。ABSK043为一款全新的具备优异活性及高度选择性的口服小分子PD-L1抑制剂。截至目前，全球已有多款PD-1/PD-L1单抗药物获批上市，但并无PD-1/PD-L1口服小分子药物获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169589451.USD","BK1161","02256","LU2488822045.USD","LU1169590202.USD","BK4023","PD"],"gpt_icon":0},{"id":"2485402841","title":"和誉(02256)：完成治疗实体瘤相关的临床研究首例胃癌患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2485402841","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485402841?lang=zh_cn&edition=full","pubTime":"2024-11-22 12:22","pubTimestamp":1732249335,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和誉(02256)公告，公司之附属公司上海和誉生物医药科技有限公司宣布，已完成“一项评估ABSK061和ABSK043联合或不联合化疗在FGFR2/3改变的转移性╱不可切除的实体瘤患者中的安全性及有效性的开放性多中心II期临床研究（方案编号：ABSK061-201）”的首例胃癌患者给药。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/ODZmNGUxMWEzNDY0MmFlZjFiZTZhNmUzMTczMTA1Mjk4MjYzMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ODZmNGUxMWEzNDY0MmFlZjFiZTZhNmUzMTczMTA1Mjk4MjYzMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948241","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2485404907","title":"和誉-B(02256.HK)附属完成ABSK061-201首例胃癌患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2485404907","media":"阿斯达克财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485404907?lang=zh_cn&edition=full","pubTime":"2024-11-22 12:04","pubTimestamp":1732248240,"startTime":"0","endTime":"0","summary":"和誉-B(02256.HK) 公布，其附属公司和誉医药已完成“一项评估ABSK061和ABSK043联合或不联合化疗在FGFR2/3改变的转移性╱不可切除的实体瘤患者中的安全性及有效性的开放性多中心II期临床研究(方案编号：ABSK061-201)”的首例胃癌患者给药。公司指，ABSK061是集团自主研发，全球临床进度最快的靶向FGFR2和FGFR3的口服选择性的强效抑制剂。ABSK043是一种靶向PD-L1的口服小分子抑制剂。(vc/a)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20211028115122107_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20211028115122107_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1398822/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2485405908","title":"和誉-B盘中异动 股价大跌5.18%报4.390港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485405908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485405908?lang=zh_cn&edition=full","pubTime":"2024-11-22 11:02","pubTimestamp":1732244579,"startTime":"0","endTime":"0","summary":"2024年11月22日早盘11时02分，和誉-B股票出现波动，股价大幅跳水5.18%。截至发稿，该股报4.390港元/股，成交量99.3万股，换手率0.15%，振幅5.62%。资金方面，该股资金流入126.828万港元，流出134.2万港元。和誉-B股票所在的生物技术行业中，整体跌幅为0.48%。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112211025998e440fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112211025998e440fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2485344034","title":"和誉-B(02256)上涨5.29%，报4.58元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485344034","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485344034?lang=zh_cn&edition=full","pubTime":"2024-11-21 14:54","pubTimestamp":1732172072,"startTime":"0","endTime":"0","summary":"11月21日，和誉-B(02256)盘中上涨5.29%，截至14:54，报4.58元/股，成交1238.91万元。和誉开曼有限责任公司是一家专注于发现和开发创新小分子肿瘤治疗药物的生物制药公司，拥有十多个专注于精确肿瘤学和肿瘤免疫治疗的创新药物研发项目，其中五项已进入临床阶段。公司的主要战略方向是小分子肿瘤精准治疗、小分子肿瘤免疫治疗及其联合疗法的研究，以满足全球患者对癌症治疗的迫切需求。截至2024年中报，和誉-B营业总收入4.97亿元、净利润2.07亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/21145445517642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2485434938","title":"和誉-B盘中异动 下午盘急速拉升5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485434938","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485434938?lang=zh_cn&edition=full","pubTime":"2024-11-21 14:54","pubTimestamp":1732172071,"startTime":"0","endTime":"0","summary":"2024年11月21日下午盘14时54分，和誉-B股票出现异动，股价急速上涨5.29%。截至发稿，该股报4.580港元/股，成交量282.6万股，换手率0.42%，振幅7.82%。和誉-B股票所在的生物技术行业中，整体涨幅为0.06%。和誉-B公司简介：和誉开曼有限责任公司是一家中国的临床阶段生物制药公司。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121145431abd3f810&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121145431abd3f810&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2485431246","title":"港股异动 | 和誉-B(02256)再涨近4% 匹米替尼III期临床结果公布 默克有较大可能行使全球商业化选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=2485431246","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485431246?lang=zh_cn&edition=full","pubTime":"2024-11-21 14:43","pubTimestamp":1732171390,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B午后再涨近4%，截至发稿，涨3.91%，报4.52港元，成交额1098.92万港元。据悉，2023年12月，和誉将pimicotinib大中华区商业化权益及全球权益优先选择权以总额最高达6.055亿美元的首付款、行权款及里程碑付款以及双位数销售分成授予默克。中金认为，pimicotinib有竞争力的TGCT和cGvHD数据有望成为默克行使海外选择权的重要参考，若行权则或在2025年为和誉带来可观的里程碑付款，增厚公司业绩。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","LU0265550946.USD","MRK","LU1974910355.USD","SG9999001440.SGD","LU0320765489.SGD","IE0002141913.USD","LU0985320562.USD","IE00B1BXHZ80.USD","LU1066051498.USD","LU2461242641.AUD","BK4516","LU0122379950.USD","LU1057294990.SGD","LU0861579265.USD","LU1989772923.USD","LU1941712348.USD","LU0203345920.USD","LU1037948897.HKD","BK4533","SG9999001176.USD","SG9999013999.USD","LU1066051225.USD","LU1430594728.SGD","LU2361045086.USD","LU0965509010.AUD","III","LU0211331839.USD","BK4534","SG9999002232.USD","LU1116320901.HKD","SGXZ57979304.SGD","IE00B2B36J28.USD","LU1983299246.USD","LU2089984988.USD","BK4559","LU1291159041.SGD","SG9999015341.SGD","LU0006306889.USD","BK4585","BK4134","LU0070302665.USD","LU0965508806.USD","SG9999015358.SGD","LU2023250504.SGD","LU1585245621.USD","LU1989771016.USD","LU0208291251.USD","LU1941712264.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"2484155652","title":"港股异动 | 和誉-B(02256)现涨超4% 匹米替尼III期临床试验结果公布 默克若选择行权将增厚公司业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2484155652","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484155652?lang=zh_cn&edition=full","pubTime":"2024-11-20 13:49","pubTimestamp":1732081752,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B(02256)盘中涨超8%，截至发稿，涨4.15%，报4.27港元，成交额633.5万港元。消息面上，和誉公布，其附属和誉医药自主研发的CSF-1R小分子抑制剂匹米替尼治疗腱鞘巨细胞瘤(TGCT)患者的MANEUVER关键3期研究，取得积极顶线结果以及匹米替尼治疗TGCT的最新1期研究结果。据悉，2023年12月，和誉医药与德国默克公司就Pimicotinib达成独家许可协议。中金认为，pimicotinib有竞争力的TGCT和cGvHD数据有望成为默克行使海外选择权的重要参考，若行权则或在2025年为和誉带来可观的里程碑付款，增厚公司业绩。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0211331839.USD","03347","LU0320765489.SGD","02256","BK1576","BK4134","LU1066051225.USD","LU0265550359.USD","IE00B1BXHZ80.USD","BK1583","IE00BLSP4452.SGD","LU1093756325.SGD","SG9999014559.SGD","BK1161","LU1057294990.SGD","LU2361044949.HKD","SG9999001176.SGD","SG9999014567.USD","LU1093756168.USD","LU1061106388.HKD","LU1989772840.SGD","LU2324357040.USD","LU1116320901.HKD","LU0234572021.USD","BK4516","LU0965509283.SGD","SGXZ57979304.SGD","LU1066051811.HKD","III","LU1941712348.USD","LU2089984988.USD","SG9999015358.SGD","BK1141","LU0265550946.USD","LU0266013472.USD","LU0965509101.SGD","LU2112291526.USD","LU1934455277.USD","LU1941712264.USD","MRK","IE0009355771.USD","SG9999001440.SGD","LU0006306889.USD","SG9999002232.USD","BK4550","IE00BLSP4239.USD","IE0002141913.USD","SG9999014542.SGD","BK4007","LU2488822045.USD"],"gpt_icon":0},{"id":"2484133275","title":"和誉-B(02256)上涨5.12%，报4.31元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484133275","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484133275?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:19","pubTimestamp":1732069197,"startTime":"0","endTime":"0","summary":"11月20日，和誉-B(02256)盘中上涨5.12%，截至10:19，报4.31元/股，成交216.71万元。和誉开曼有限责任公司是一家专注于发现和开发创新小分子肿瘤治疗药物的生物制药公司，拥有十多个专注于精确肿瘤学和肿瘤免疫治疗的创新药物研发项目，其中五项已进入临床阶段。公司的主要战略方向是小分子肿瘤精准治疗、小分子肿瘤免疫治疗及其联合疗法的研究，以满足全球患者对癌症治疗的迫切需求。截至2024年中报，和誉-B营业总收入4.97亿元、净利润2.07亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/20101945475844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2484368781","title":"和誉-B盘中异动 早盘急速拉升5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484368781","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484368781?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:19","pubTimestamp":1732069192,"startTime":"0","endTime":"0","summary":"2024年11月20日早盘10时19分，和誉-B股票出现波动，股价大幅拉升5.12%。截至发稿，该股报4.310港元/股，成交量51.7万股，换手率0.08%，振幅6.10%。资金方面，该股资金流入155.127万港元，流出40.113万港元。和誉-B股票所在的生物技术行业中，整体涨幅为1.57%。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112010195298e43a45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112010195298e43a45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2484947876","title":"和誉-B(02256)下跌5.06%，报4.13元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484947876","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484947876?lang=zh_cn&edition=full","pubTime":"2024-11-18 13:10","pubTimestamp":1731906606,"startTime":"0","endTime":"0","summary":"11月18日，和誉-B(02256)盘中下跌5.06%，截至13:10，报4.13元/股，成交796.92万元。和誉开曼有限责任公司是一家专注于发现和开发创新小分子肿瘤治疗药物的生物制药公司，拥有十多个专注于精确肿瘤学和肿瘤免疫治疗的创新药物研发项目，其中五项已进入临床阶段。公司的主要战略方向是小分子肿瘤精准治疗、小分子肿瘤免疫治疗及其联合疗法的研究，以满足全球患者对癌症治疗的迫切需求。截至2024年中报，和誉-B营业总收入4.97亿元、净利润2.07亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/18131045390740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2484203692","title":"和誉-B盘中异动 急速下跌5.06%报4.130港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484203692","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484203692?lang=zh_cn&edition=full","pubTime":"2024-11-18 13:10","pubTimestamp":1731906606,"startTime":"0","endTime":"0","summary":"2024年11月18日下午盘13时10分，和誉-B股票出现波动，股价大幅下挫5.06%。资金方面，该股资金流入375.114万港元，流出337.301万港元。和誉-B股票所在的生物技术行业中，整体跌幅为0.67%。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。该信息摘要如下：中泰证券发布研报称，维持和誉-B“买入”评级，预计2024-2026年公司收入、其他收入及收益合计分别为5.6亿元、6.4亿元、6.9亿元，净利润分别为0.02亿元、0.3亿元、0.6亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118131006a241b3cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118131006a241b3cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2484148692","title":"和誉－Ｂ(02256)股价下跌5.057%，现价港币$4.13","url":"https://stock-news.laohu8.com/highlight/detail?id=2484148692","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484148692?lang=zh_cn&edition=full","pubTime":"2024-11-18 13:10","pubTimestamp":1731906600,"startTime":"0","endTime":"0","summary":"[下跌股]和誉－Ｂ(02256) 股价在下午01:10比前收市价下跌5.057%，现股价为港币$4.13。至目前为止，今日最高价为$4.33，而最低价为$4.13。总成交量为185.6万股，总成交金额为港币$783.239万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2411181010/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2483679605","title":"中泰证券：匹米替尼全球III期临床告捷 维持和誉-B(02256)“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2483679605","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483679605?lang=zh_cn&edition=full","pubTime":"2024-11-16 15:19","pubTimestamp":1731741550,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中泰证券发布研报称，维持和誉-B“买入”评级，预计2024-2026年公司收入、其他收入及收益合计分别为5.6亿元、6.4亿元、6.9亿元，净利润分别为0.02亿元、0.3亿元、0.6亿元。匹米替尼1b期更新数据中ORR进一步提高，凭借耐受性优势有望通过长期用药极大满足患者的临床需求。匹米替尼针对cGVHD的II期临床研究进行中，POC数据将在ASH2024展示;针对一线胰腺癌的II期临床研究亦在有序推进中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600918","02256","III"],"gpt_icon":0},{"id":"2483130920","title":"和誉-B(02256)下跌5.11%，报4.46元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483130920","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483130920?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:30","pubTimestamp":1731465017,"startTime":"0","endTime":"0","summary":"11月13日，和誉-B(02256)盘中下跌5.11%，截至10:30，报4.46元/股，成交6363.17万元。和誉开曼有限责任公司是一家专注于发现和开发创新小分子肿瘤治疗药物的生物制药公司，拥有十多个专注于精确肿瘤学和肿瘤免疫治疗的创新药物研发项目，其中五项已进入临床阶段。公司的主要战略方向是小分子肿瘤精准治疗、小分子肿瘤免疫治疗及其联合疗法的研究，以满足全球患者对癌症治疗的迫切需求。截至2024年中报，和誉-B营业总收入4.97亿元、净利润2.07亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/13103045232035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2483015159","title":"和誉-B盘中异动 股价大跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483015159","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483015159?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:30","pubTimestamp":1731465010,"startTime":"0","endTime":"0","summary":"2024年11月13日早盘10时30分，和誉-B股票出现异动，股价快速下挫5.11%。截至发稿，该股报4.460港元/股，成交量1463.4万股，换手率2.15%，振幅4.89%。资金方面，该股资金流入570.701万港元，流出529.237万港元。和誉-B股票所在的生物技术行业中，整体跌幅为2.11%。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113103010971a62e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113103010971a62e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2483015214","title":"和誉－Ｂ(02256)股价下跌5.106%，现价港币$4.46","url":"https://stock-news.laohu8.com/highlight/detail?id=2483015214","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483015214?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:30","pubTimestamp":1731465000,"startTime":"0","endTime":"0","summary":"[下跌股]和誉－Ｂ(02256) 股价在上午10:30比前收市价下跌5.106%，现股价为港币$4.46。至目前为止，今日最高价为$4.69，而最低价为$4.46。总成交量为1.463千万股，总成交金额为港币$6.363千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2411131080/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2483096536","title":"和誉(02256.HK)附属研究结果支持匹米替尼在全球开发和治疗TGCT推荐剂量","url":"https://stock-news.laohu8.com/highlight/detail?id=2483096536","media":"阿斯达克财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483096536?lang=zh_cn&edition=full","pubTime":"2024-11-13 08:13","pubTimestamp":1731456780,"startTime":"0","endTime":"0","summary":"和誉(02256.HK) 公布，其附属和誉医药在2024年美国定量药理学大会上展示其自主研发的口服、高选择性、活性CSF-1R小分子抑制剂匹米替尼(ABSK021)治疗腱鞘巨细胞瘤(TGCT)的模型引导的剂量选择研究结果。研究结果支持50mg QD作为匹米替尼在全球开发和治疗TGCT的推荐剂量。(jl/w)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20211028115122107_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20211028115122107_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1396158/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2488822045.USD","02256","BK1161"],"gpt_icon":0},{"id":"2483064742","title":"和誉-B(02256)：和誉医药在2024年ACoP会议展示匹米替尼模型引导的剂量选择研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2483064742","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483064742?lang=zh_cn&edition=full","pubTime":"2024-11-13 07:04","pubTimestamp":1731452659,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 公布，公司附属和誉医药在2024年美国定量药理学大会上展示了其自主研发的口服、高选择性、活性CSF-1R小分子抑制剂匹米替尼治疗腱鞘巨细胞瘤的模型引导的剂量选择研究结果。此次发布的研究综合药物代谢动力学、安全性和有效性信息，用于指导模型引导剂量的选择。这些模型被用于确定匹米替尼的最佳剂量选择，研究结果支持50mg QD作为匹米替尼在全球开发和治疗TGCT的推荐剂量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","BK1574","09939","LU2488822045.USD","02256","159938"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbisko.com","stockEarnings":[{"period":"1week","weight":0.0404},{"period":"1month","weight":0.2026},{"period":"3month","weight":0.4984},{"period":"6month","weight":0.3862},{"period":"1year","weight":0.2861},{"period":"ytd","weight":0.2685}],"compareEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":-0.0438},{"period":"3month","weight":0.1129},{"period":"6month","weight":0.0533},{"period":"1year","weight":0.1052},{"period":"ytd","weight":0.1498}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和誉开曼有限责任公司是一家中国的临床阶段生物制药公司。该公司致力于发现及开发创新且差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK011是一种有效的高选择性小分子成纤维细胞生长因子受体4（FGFR4）抑制剂。ABSK091是一种分子靶向候选产品，是FGFR亚型1、2及3的高效及选择性抑制剂。该公司的产品主要用于治疗肝细胞癌（HCC）、尿路上皮癌（UC）及胃癌（GC）。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.206623},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.021578},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.062878},{"month":4,"riseRate":0.333333,"avgChangeRate":0.018452},{"month":5,"riseRate":0,"avgChangeRate":-0.043841},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.013147},{"month":7,"riseRate":0.666667,"avgChangeRate":0.049332},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.050943},{"month":9,"riseRate":0.666667,"avgChangeRate":0.042883},{"month":10,"riseRate":0.666667,"avgChangeRate":0.004984},{"month":11,"riseRate":0.75,"avgChangeRate":0.204437},{"month":12,"riseRate":0,"avgChangeRate":-0.122261}],"exchange":"SEHK","name":"和誉-B","nameEN":"ABBISKO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和誉-B,02256,和誉-B股票,和誉-B股票老虎,和誉-B股票老虎国际,和誉-B行情,和誉-B股票行情,和誉-B股价,和誉-B股市,和誉-B股票价格,和誉-B股票交易,和誉-B股票购买,和誉-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}